WSJ: They got cancer, and then their drugs were rationed
University of Cincinnati Cancer Center physician discusses chemotherapy shortage
Across the U.S., a monthslong shortage of critical chemotherapies have forced doctors and pharmacists to stretch their supplies, according to an article in the Wall Street Journal.
Some patients have received less treatment or lengthened the time between treatments, while others have had to turn to second-line options.
The chemotherapies in shortage are cheap, generic drugs that don’t make much profit —and few companies want to manufacture them. After the Food and Drug Administration found quality problems late last year at a major manufacturing facility in India, the company halted its production of two of these drugs, cisplatin and carboplatin, sparking the scarcity.
These (drugs) are the backbones of treatment for many of these cancers, and it is frustrating that this is where we are.
Davendra Sohal University of Cincinnati Cancer Center
At least two dozen patients at the University of Cincinnati Cancer Center have had their treatment disrupted, said Davendra Sohal, MD, an oncologist who treats gastrointestinal cancer patients; he is associate director of clinical research at the Cancer Center. Those already in clinical trials or who can be cured take priority when rationing the drugs, he said, followed by those with progressing disease.
Some patients who are dealing with more stable, chronic disease have had to miss a dose in order to manage the supply, he added. A patient who travels weekly from West Virginia for treatment made the trip last month to find out that there wasn’t any drug, Sohal said. A few weeks ago, only half of the colorectal cancer patients could get their scheduled dose.
“The other half we called and said sorry, not this week,” Sohal said. “These are the backbones of treatment for many of these cancers, and it is frustrating that this is where we are.”
Read the full Wall Street Journal story.
Learn more about the University of Cincinnati Cancer Center.
Featured image at top of Davendra Sohal. Photo credit/UC Health
Innovation Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.